“Successful clinical results of a focal individualised mini-metal implant for focal cartilage lesions in the knee” by T. Spalding, C. Stevenson, M. Lind, K. Eriksson, T. Jung, G. Histol, P. Emans, and J. Holz has been accepted as a presentation at the BASK (British Association for Surgery of the Knee) annual meeting 2018 in Leicester, UK, which will take place on March 20-21.
The clinical outcome for a European cohort of patients treated with the Episealer® knee implant will be presented.
“We are of course delighted with the fact that clinical results from the use of Episealer® knee implants will be presented at this very important meeting. Treating this middle-aged patient group has been a challenge for a very long time, and we are glad for these very promising results” says Pål Ryfors, CEO of Episurf Medical.
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalized treatment alternatives. Episurf Medical’s Episealer® personalized implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.30 CET on 12 March 2018.
CisionBlockPro\Cision\FeedItem Object
(
[HtmlCompanyInformation:protected] => <p style="font-size: 10pt;font-family: arial,helvetica,sans-serif;"><span style="font-size: 10pt;"><strong></strong></span></p>
[HtmlContact:protected] => <p style="font-size: 10pt;font-family: arial,helvetica,sans-serif;"><span style="font-size: 10pt;"><strong></strong></span></p>
[HtmlTitle:protected] => <h1 style="font-family: arial,helvetica,sans-serif;">Promising clinical results from use of Episealer® will be presented at the annual meeting of British Association for Surgery of the Knee</h1>
[HtmlHeader:protected] =>
[HtmlIntro:protected] => <p style="font-size: 10pt;font-family: arial,helvetica,sans-serif;"><span style="font-size: 10pt;"><strong></strong></span></p>
[Body:protected] => "Successful clinical results of a focal individualised mini-metal implant for focal cartilage lesions in the knee" by T. Spalding, C. Stevenson, M. Lind, K. Eriksson, T. Jung, G. Histol, P. Emans, and J. Holz has been accepted as a presentation at the BASK (British Association for Surgery of the Knee) annual meeting 2018 in Leicester, UK, which will take place on March 20-21.
The clinical outcome for a European cohort of patients treated with the Episealer® knee implant will be presented.
“We are of course delighted with the fact that clinical results from the use of Episealer® knee implants will be presented at this very important meeting. Treating this middle-aged patient group has been a challenge for a very long time, and we are glad for these very promising results” says Pål Ryfors, CEO of Episurf Medical.
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalized treatment alternatives. Episurf Medical’s Episealer® personalized implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.30 CET on 12 March 2018.
[HtmlBody:protected] => <p style="font-family: arial, helvetica, sans-serif; font-size: 10pt;"><em><span style="font-size: 10pt;">"Successful clinical results of a focal individualised mini-metal implant for focal cartilage lesions in the knee"</span></em><span style="font-size: 10pt;"> by T. Spalding, C. Stevenson, M. Lind, K. Eriksson, T. Jung, G. Histol, P. Emans, and J. Holz has been accepted as a presentation at the BASK (British Association for Surgery of the Knee) annual meeting 2018 in Leicester, UK, which will take place on March 20-21. </span> </p>
<p style="font-family: arial, helvetica, sans-serif; font-size: 10pt;"><span style="font-size: 10pt;">The clinical outcome for a European cohort of patients treated with the Episealer</span><strong><span style="font-size: 10pt;">®</span></strong><span style="font-size: 10pt;"> knee implant will be presented.</span> </p>
<p style="font-family: arial, helvetica, sans-serif; font-size: 10pt;"><span style="font-size: 10pt;">“We are of course delighted with the fact that clinical results from the use of Episealer® knee implants will be presented at this very important meeting. Treating this middle-aged patient group has been a challenge for a very long time, and we are glad for these very promising results” says Pål Ryfors, CEO of Episurf Medical.</span> </p>
<p style="font-family: arial, helvetica, sans-serif; font-size: 10pt;"><span style="font-size: 10pt;"><strong>For more information, please contact:</strong></span></p>
<p style="font-family: arial, helvetica, sans-serif; font-size: 10pt;"><span style="font-size: 10pt;">Pål Ryfors, CEO, Episurf Medical</span></p>
<p style="font-family: arial, helvetica, sans-serif; font-size: 10pt;"><span style="font-size: 10pt;">Tel:</span><span style="font-size: 10pt;">+46 (0) 709 62 36 69</span></p>
<p style="font-family: arial, helvetica, sans-serif; font-size: 10pt;"><span style="font-size: 10pt;">Email: <a href="mailto:pal.ryfors@episurf.com">pal.ryfors@episurf.com</a></span></p>
<p style="font-family: arial, helvetica, sans-serif; font-size: 10pt;"><span style="font-size: 10pt;"><strong>About Episurf Medical</strong></span></p>
<p style="font-family: arial, helvetica, sans-serif; font-size: 10pt;"><span style="font-size: 10pt;"><em>Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalized treatment alternatives. Episurf Medical’s Episealer® personalized implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.</em></span></p>
<p style="font-family: arial, helvetica, sans-serif; font-size: 10pt;"><span style="font-size: 10pt;"><em>This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.30 CET on 12 March 2018.</em></span></p>
[ServiceCategories:protected] => Array
(
[0] => CisionBlockPro\Cision\ServiceCategory Object
(
[ServiceName:protected] => EU Transparency SE
[Name:protected] => SeFsaCategoryCode
[Value:protected] => S6
)
[1] => CisionBlockPro\Cision\ServiceCategory Object
(
[ServiceName:protected] => OMX Filing (OMX CNS)
[Name:protected] => OMX CategoryCode
[Value:protected] => 428
)
[2] => CisionBlockPro\Cision\ServiceCategory Object
(
[ServiceName:protected] => Twitter
[Name:protected] => Twitter
[Value:protected] => 9341
)
[3] => CisionBlockPro\Cision\ServiceCategory Object
(
[ServiceName:protected] => LinkedIn
[Name:protected] => LinkedIn
[Value:protected] => 9309
)
[4] => CisionBlockPro\Cision\ServiceCategory Object
(
[ServiceName:protected] => Facebook
[Name:protected] => Facebook
[Value:protected] => 9307
)
)
[LogoUrl:protected] => https://mb.cision.com/Public/14691/logo/96c29c854b230ac3_org.png
[CompanyInformation:protected] =>
[Contact:protected] =>
[Header:protected] =>
[Keywords:protected] => Array
(
[0] => Episurf Medical
[1] => EpiSurf
)
[QuickFacts:protected] => Array
(
)
[Categories:protected] => Array
(
)
[Videos:protected] => Array
(
)
[Files:protected] => Array
(
[0] => CisionBlockPro\Cision\File Object
(
[IsMain:protected] => 1
[MediaType:protected] => File
[Url:protected] => https://mb.cision.com/Main/14691/2469894/803957.pdf
[FileName:protected] => wkr0006.pdf
[Title:protected] => Promising clinical results from use of Episealer® will be presented at the annual meeting of British Association for Surgery of the Knee
[Description:protected] => Promising clinical results from use of Episealer® will be presented at the annual meeting of British Association for Surgery of the Knee
[CreateDate:protected] => 2018-03-12T07:30:14Z
[Keywords:protected] => Array
(
)
[Extension:protected] => pdf
)
)
[Quotes:protected] => Array
(
)
[ExternalLinks:protected] => Array
(
)
[EmbeddedItems:protected] => Array
(
)
[Id:protected] => 2845045
[EncryptedId:protected] => F845A416140316F7
[IsRegulatory:protected] => 1
[PublishDate:protected] => 2018-03-12T07:30:00Z
[LastChangeDate:protected] => 2018-03-12T07:30:14Z
[Title:protected] => Promising clinical results from use of Episealer® will be presented at the annual meeting of British Association for Surgery of the Knee
[Intro:protected] =>
[IptcCode:protected] => 04016003
[InformationType:protected] => PRM
[LanguageCode:protected] => en
[CountryCode:protected] => se
[CanonicalUrl:protected] =>
[CisionWireUrl:protected] => https://news.cision.com/episurf/r/promising-clinical-results-from-use-of-episealer--will-be-presented-at-the-annual-meeting-of-british,c2469894
[LanguageVersions:protected] => Array
(
)
[Images:protected] => Array
(
)
[Tickers:protected] => Array
(
[0] => stdClass Object
(
[Symbol] => EPIS B
[ISIN] => SE0003491562
[PrimaryListing] => 1
[IsShare] => 1
[MarketPlaceSymbol] => STO
[MarketPlaceName] => Stockholmsbörsen
[MarketPlaceBloombergCode] => SS
[MarketPlaceMarketWireCode] => OMX
[MarketPlaceIsRegulated] => 1
[MarketPlaceCountryCode] => SE
)
)
)